Small dense LDL percentage reports the fraction of your LDL cholesterol carried by the smallest, densest LDL subfraction, the most atherogenic type. This metric is distinct from LDL Small (ION), which counts particles in nmol/L.
Elevated small-dense-LDL % is tightly associated with insulin resistance, metabolic dysfunction, and higher cardiovascular event rates even when total LDL-C is normal. Lifestyle interventions targeting insulin sensitivity typically shift particles toward larger, less atherogenic sizes.
Optimal Small Dense LDL: 0-20 %.
Typically re-tested every 12 weeks.
Small dense LDL (often written sdLDL) is a subclass of low-density lipoprotein that carries less cholesterol per particle and sits at the small, dense end of the LDL size range 1.
LDL is not one uniform thing. A standard cholesterol panel reports how much cholesterol is being carried inside LDL particles, but it says nothing about how many particles are doing the carrying or how big they are. Particle size varies across a spectrum, and when the smaller, denser particles predominate, lipid specialists describe the pattern as LDL phenotype B 3.
The mechanism starts upstream, with triglycerides. When triglyceride-rich lipoproteins are abundant, cholesteryl ester transfer protein shifts triglyceride into LDL particles in exchange for cholesteryl ester. Lipases then strip that triglyceride back out, and what remains is a shrunken, denser, cholesterol-poor particle 1. This is why small dense LDL so often travels with high triglycerides and low HDL rather than appearing on its own.
The size change matters because it alters how the particle behaves. Research suggests these particles bind less readily to the LDL receptor, which lengthens the time they spend circulating, and that they pass into the artery wall more easily, where they bind to the proteoglycan matrix and are more susceptible to oxidative modification 2. Those same properties are the ones described in the literature as making the subclass more atherogenic than larger, buoyant LDL 3.
Laboratories report the result either as a concentration of cholesterol carried in the small dense fraction (mg/dL) or as the percentage of total LDL falling into that size band. The percentage form is what the ranges below refer to.
It matters because particle quality adds information that cholesterol concentration alone can miss, and because the subclass has been studied directly against cardiovascular endpoints.
In a large prospective analysis, cholesterol carried in small dense LDL was associated with incident cardiovascular disease, including in participants whose standard LDL cholesterol was not markedly elevated 4. A review of the measurement and the outcome data reaches a similar conclusion, reporting consistent associations between small dense LDL cholesterol and cardiovascular endpoints across cohorts 5.
Mechanistic work lines up with that. Studies indicate that small, dense particles contribute disproportionately to the initiation and progression of atherosclerotic lesions because of their longer residence time, easier entry into the intima and greater oxidative susceptibility 2. A 2025 review frames the subclass as an underestimated driver of atherosclerosis for those reasons 1.
One honest caveat. There is a long-running debate about whether the risk signal belongs to particle size itself or to the fact that people with small particles usually have more particles overall, and reviews of that question argue that particle number carries much of the statistical weight 6. In practice, the two travel together, which is why a size result is most useful read next to a particle count rather than alone.
A single value does not determine anyone's future. What it does is describe the current shape of your lipid transport, and that is worth discussing with a clinician alongside the rest of your panel.
Most laboratories regard a small dense LDL fraction up to roughly 30 % of total LDL as within the typical reference range. FitScript's optimal range is tighter.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| Small dense LDL (% of total LDL) | 0 to 30 % | 0 to 20 % |
Reference ranges vary by laboratory, assay, age and sex, so always read your result against the range printed on your own report. FitScript's optimal range is an optimization target, not a diagnostic cut-off, and a value outside it is not a diagnosis of anything.
Sex-specific and age-specific cut-points are not applied here because they are not supplied for this marker. Methods differ too. Some laboratories separate particles physically by density or electrophoretic mobility, others use a direct homogeneous assay, and there are published equations that estimate small dense LDL cholesterol from a standard lipid profile, an approach reviewed in the recent lipidology literature 7. Because those approaches do not produce identical numbers, comparing results across laboratories is less reliable than tracking the same assay over time.
A high result means a larger share of your LDL is being carried in the small, dense particles that research associates most strongly with artery wall injury 1. It is an observation about particle distribution, not a verdict on your arteries.
Symptoms people report. Essentially none. This subclass is silent, and nobody feels their LDL particle size. What people sometimes notice are the features that accompany the pattern, such as gradual central weight gain or a lipid panel that keeps showing high triglycerides and low HDL. Those are clues to the metabolic context, not symptoms of the marker itself.
Common causes. Elevated small dense LDL is commonly observed in people with metabolic syndrome, insulin resistance, type 2 diabetes and obesity 1. Excess body fat is part of that picture, and research suggests that the small dense phenotype shifts when adiposity normalises 13. Chronic inflammation is a second theme. Elevated small dense LDL cholesterol has been reported in people with several different chronic inflammatory diseases 8, and in people with psoriasis estimated small dense LDL cholesterol was studied as a predictor of high-risk coronary plaque features 10. Liver status matters as well, with one multicentre study finding a higher LDL migration index, an indicator of small dense LDL, in non-alcoholic steatohepatitis than in simple fatty liver 9. Regulatory biology contributes too, since plasma PCSK9 correlated positively with small dense LDL in a community-dwelling population, though not in the diabetic participants after adjustment 11. Altered small dense LDL profiles have also been described in long-standing, well-controlled type 1 diabetes 12.
Long-term health impact. The concern is cumulative rather than immediate. Higher small dense LDL cholesterol is associated with incident cardiovascular disease over years of follow-up 4, and the mechanistic literature attributes that to the subclass accelerating lesion development in the artery wall 2.
Next step. A result above the standard range, particularly alongside high triglycerides, low HDL or a high particle count, is worth discussing with a clinician promptly so the whole lipid and metabolic picture can be reviewed together. Never set an abnormal result aside on your own.
A low result means most of your LDL is being carried in larger, more buoyant particles, which is generally the more favourable distribution 3.
Symptoms people report. None.
Common causes. A low fraction can follow a change in metabolic status. Research suggests that normalising excess adiposity is associated with reversal of the small dense subclass phenotype 13, and one study reported that LDL particle size and antioxidant HDL function improved after sustained virological response in people with chronic hepatitis C 14.
Long-term health impact. Reassuring, with a caveat. A low fraction does not mean low cardiovascular risk on its own, because reviews of the size versus number question argue that total atherogenic particle count carries much of the risk signal 6. Someone can have predominantly large particles and still carry a high particle number. That is why a favourable size result should be read next to LDL cholesterol, particle number and apoB rather than used to dismiss them.
Next step. Treat a low result as one supportive data point and keep tracking the rest of the panel with your clinician.
Several things, some of them about the test and some about your physiology in the weeks before it.
Testing conditions. Because the subclass sits downstream of triglyceride metabolism, anything that moves triglycerides on the day can move the reading. Many laboratories ask for a fasting sample for this reason. Acute illness, recent heavy alcohol intake and a period of rapid weight change can all shift a lipid panel temporarily, so a result taken during an unsettled stretch is best repeated once things are stable. Assay choice matters as much as biology here, since physical separation methods, direct assays and profile-based estimation equations do not return identical values 7.
Medications. Prescription medicines that influence lipid or glucose metabolism can change the result, and so can changes in dose or timing. No medication should be started, stopped or adjusted on the basis of this marker. A licensed provider evaluates whether any treatment is appropriate after reviewing your full history and labs, and this page gives no dosing or administration guidance of any kind.
Habits. Dietary composition is the most studied lever. A review of small dense LDL cholesterol and dietary strategies reports that patterns which lower triglycerides tend to shift the subclass distribution toward larger particles 5. Body composition is the other. Research suggests that normalising excess adiposity is associated with reversal of the small dense phenotype rather than merely blunting it 13. Both take weeks to months to show up in bloodwork, so retesting too early usually measures noise.
Underlying conditions. Inflammatory and hepatic status can pull the result in either direction, which is why it has been studied in people with chronic inflammatory disease 8 and in fatty liver disease 9.
FitScript does not currently test small dense LDL in a panel. If you already have a result from another laboratory, you can upload your labs so that Atlas, FitScript's AI health advisor, can read it alongside the markers that are measured, including the rest of your lipid and insulin picture.
That context is the point. A size percentage on its own answers very little, while the same number read next to triglycerides, HDL, particle count and fasting insulin describes a coherent metabolic pattern. Atlas uses those relationships to write your FitScript, the personalised output generated from your own biology, and it flags values that sit outside standard or optimal ranges rather than labelling them as a condition.
The membership itself is built around repeated measurement, with 150+ biomarkers tested per year, so changes are read as trends instead of single snapshots. Where a result raises a question that a prescription might address, a licensed provider reviews the member and decides whether any treatment is appropriate. Interpretation support is not a clinical decision, and nothing here replaces one.
None of these is a substitute for the others, and each answers a different question about the same lipid system.
Together these turn a single size percentage into a readable pattern, which is the only way it should be used.
Small dense LDL describes the share of your LDL carried in smaller, denser, longer-circulating particles. Research associates a higher share with a more atherogenic profile and with incident cardiovascular disease, usually in the company of high triglycerides, low HDL and insulin resistance 4. Standard laboratory ranges regard up to roughly 30 % of total LDL as typical, while FitScript's optimal range is 0 to 20 %. A result outside either range is a prompt to look at the whole panel, not a diagnosis, and the levers with the most published support are metabolic rather than cosmetic.
This article is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider before changing anything.
For related reading on how particle measures and cholesterol numbers can disagree, see can you have high ldl and low apob, and for the broader picture on lipid management, see how to reduce ldl cholesterol.
It measures how much of your LDL is being carried in the smaller, denser particles rather than in larger, buoyant ones. Laboratories report it either as a percentage of total LDL or as the cholesterol concentration in that fraction. It describes particle distribution, not a condition.
No. LDL cholesterol tells you how much cholesterol the particles are carrying, while this marker tells you what size those particles tend to be. The two can disagree, which is why a size result is most useful when it is read next to LDL cholesterol and a particle count.
Many laboratories ask for a fasting sample because the result tracks closely with triglycerides, which rise after eating. Follow the instruction printed on your requisition, and keep your preparation consistent between tests so the numbers stay comparable.
Most laboratories regard up to roughly 30 % of total LDL as within the typical reference range. FitScript's optimal range is 0 to 20 %, which is an optimization target rather than a diagnostic cut-off. Always read your own report against the range printed on it.
Yes. It reflects your current metabolic state and can shift with body composition, dietary pattern, illness and medication changes. Changes usually take weeks to months to show up, so retesting too soon often measures day-to-day variation rather than real progress.
Not currently. If you already have a result from another laboratory, you can upload your existing labs and Atlas will read it alongside the markers FitScript does measure, including your lipid panel and fasting insulin.
Bring it to a clinician along with the rest of your lipid panel and your metabolic markers, rather than acting on the single number. A value well outside the standard range is worth discussing promptly, and a licensed provider is the one who decides whether any treatment is appropriate.
No. A favourable particle size is one supportive data point, but total particle count, LDL cholesterol, blood pressure, family history and other factors all contribute. Keep tracking the full picture with your clinician instead of relying on one marker.